Literature DB >> 28250856

Usefulness of SPECT/CT in Parathyroid Lesion Detection in Patients with Thyroid Parenchymal 99mTc-Sestamibi Retention.

Sang Hyun Hwang1, Yumie Rhee2, Mijin Yun1, Jung Hyun Yoon3, Jeong Won Lee4, Arthur Cho1.   

Abstract

PURPOSE: Parathyroid adenoma detection with dual-phase 99mTc-sestamibi (MIBI) scintigraphy depends on differential MIBI washout from thyroid. However, autoimmune thyroid disease (AITD) may cause MIBI to be retained in the thyroid gland and reduce parathyroid detection. We evaluated the impact of AITD on MIBI thyroid retention and additional benefit of SPECT/CT in these patients.
METHODS: Dual phase planar MIBI and SPECT/CT was performed on 82 patients. SPECT/CT was performed immediately after delayed planar scan. Thyroid density (Hounsfield unit, CT-HU) and size were measured on CT component of SPECT/CT. MIBI uptake in early scans and retention in delayed scans were visually graded and correlated with clinical factors and CT findings. Finally, planar and SPECT/CT findings were compared for parathyroid lesion visualization according to thyroid MIBI retention.
RESULTS: In early scan, multivariate analysis showed only thyroid size predicted early uptake. In delayed scan, multivariate analysis showed higher visual grade in early scan, lower CT-HU or AITD were significant predictors for delayed thyroid parenchymal retention. Overall, ten more parathyroid lesions were visualized on SPECT/CT compared to planar scans (57 vs. 47, p = 0.002). SPECT/CT was especially more useful in patients with thyroidal MIBI retention, as eight out of the ten additional lesions detected were found in patients with thyroid MIBI retention.
CONCLUSION: AITD is an important factor for MIBI thyroid parenchymal retention on delayed scans, and may impede parathyroid lesion detection. Patients with MIBI retention in the thyroid parenchyma on delayed scans are likely to benefit from an additional SPECT/CT.

Entities:  

Keywords:  99mTc-sestamibi scintigraphy; Autoimmune thyroid disease; Parathyroid; SPECT/CT

Year:  2016        PMID: 28250856      PMCID: PMC5313463          DOI: 10.1007/s13139-016-0438-5

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  20 in total

1.  Correlation of CT values, iodine concentration, and histological changes in the thyroid.

Authors:  Y Imanishi; N Ehara; T Shinagawa; D Tsujino; I Endoh; K Baba; Y Kanemaki; S Iida; M Hayakawa; O Miyazaki; K Shirakawa; S Nosaka
Journal:  J Comput Assist Tomogr       Date:  2000 Mar-Apr       Impact factor: 1.826

Review 2.  Radionuclide imaging of the parathyroid glands.

Authors:  Christopher J Palestro; Maria B Tomas; Gene G Tronco
Journal:  Semin Nucl Med       Date:  2005-10       Impact factor: 4.446

3.  Preoperative ⁹⁹mTc-sestamibi scintigraphy in patients with primary hyperparathyroidism and concomitant nodular goiter: comparison of SPECT-CT, SPECT, and planar imaging.

Authors:  Babak Shafiei; Samaneh Hoseinzadeh; Fereidoun Fotouhi; Hadi Malek; Fereidoun Azizi; Adel Jahed; Farzad Hadaegh; Mohammadtaghi Salehian; Hossein Parsa; Hamid Javadi; Majid Assadi
Journal:  Nucl Med Commun       Date:  2012-10       Impact factor: 1.690

4.  Efficacy of ⁹⁹mTc-sestamibi SPECT/CT for minimally invasive parathyroidectomy: comparative study with ⁹⁹mTc-sestamibi scintigraphy, SPECT, US and CT.

Authors:  Yong-Il Kim; Young Ho Jung; Ki Tae Hwang; Ho-Young Lee
Journal:  Ann Nucl Med       Date:  2012-08-09       Impact factor: 2.668

5.  Comparison of technetium-99m-MIBI, technetium-99m-tetrofosmin, ultrasound and MRI for localization of abnormal parathyroid glands.

Authors:  M Ishibashi; H Nishida; Y Hiromatsu; K Kojima; E Tabuchi; N Hayabuchi
Journal:  J Nucl Med       Date:  1998-02       Impact factor: 10.057

6.  Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase (99m)Tc-sestamibi parathyroid scintigraphy.

Authors:  William C Lavely; Sibyll Goetze; Kent P Friedman; Jeffrey P Leal; Zhe Zhang; Elizabeth Garret-Mayer; Alan P Dackiw; Ralph P Tufano; Martha A Zeiger; Harvey A Ziessman
Journal:  J Nucl Med       Date:  2007-06-15       Impact factor: 10.057

Review 7.  Amiodarone and thyroid.

Authors:  Silvia A Eskes; Wilmar M Wiersinga
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

8.  Visualization of suppressed thyroid tissue by Tc-99m MIBI.

Authors:  C H Kao; W Y Lin; S J Wang; S H Yeh
Journal:  Clin Nucl Med       Date:  1991-11       Impact factor: 7.794

9.  Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study)

Authors:  R Taillefer; Y Boucher; C Potvin; R Lambert
Journal:  J Nucl Med       Date:  1992-10       Impact factor: 10.057

10.  Computed tomography in the evaluation of thyroid disease.

Authors:  P M Silverman; G E Newman; M Korobkin; J B Workman; A V Moore; R E Coleman
Journal:  AJR Am J Roentgenol       Date:  1984-05       Impact factor: 3.959

View more
  4 in total

Review 1.  KSNM60 in Nuclear Endocrinology: from the Beginning to the Future.

Authors:  Chae Moon Hong; Young Jin Jeong; Hae Won Kim; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2022-01-24

2.  Dual-phase 99mTc-MIBI imaging and the expressions of P-gp, GST-π, and MRP1 in hyperparathyroidism.

Authors:  Jianjun Xue; Yan Liu; Danrong Yang; Yan Yu; Qianqian Geng; Ting Ji; Lulu Yang; Qi Wang; Yuanbo Wang; Xueni Lu; Aimin Yang
Journal:  Nucl Med Commun       Date:  2017-10       Impact factor: 1.690

3.  Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of 99mTc-sestamibi SPECT/CT.

Authors:  Antonios Tzortzakakis; Ove Gustafsson; Mattias Karlsson; Linnea Ekström-Ehn; Rammin Ghaffarpour; Rimma Axelsson
Journal:  EJNMMI Res       Date:  2017-03-29       Impact factor: 3.138

4.  Is dual-phase SPECT/CT with 99mTc-sestamibi better than single-phase SPECT/CT for lesion localization in patients with hyperparathyroidism?

Authors:  Suk Hyun Lee; Eonwoo Shin; Sejin Ha; Jungsu S Oh; Dong Eun Song; Jin-Sook Ryu
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.